CRPC And HRPCA Therapeutics Market Report 2026


What Are The Projected Market Size And CAGR For The Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market By The Conclusion Of 2030?
The castration-resistant prostate cancer (crpc) or hormone-refractory prostate cancer (hrpca) therapeutics market size has grown strongly in recent years. It will grow from $8.43 billion in 2025 to $8.92 billion in 2026 at a compound annual growth rate (CAGR) of 5.8%. The growth in the historic period can be attributed to prostate cancer prevalence, hormone therapy resistance, oncology drug innovation, hospital-based cancer care, aging male population.

The castration-resistant prostate cancer (crpc) or hormone-refractory prostate cancer (hrpca) therapeutics market size is expected to see strong growth in the next few years. It will grow to $11.04 billion in 2030 at a compound annual growth rate (CAGR) of 5.5%. The growth in the forecast period can be attributed to biomarker-driven treatment, advanced targeted therapies, oral oncology adoption, oncology pipeline expansion, personalized cancer care. Major trends in the forecast period include rising use of androgen receptor inhibitors, growth of parp inhibitor therapies, expansion of combination treatment regimens, increased focus on precision oncology, shift toward oral oncology drugs.

Claim Your Free Report Sample Today:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24495&type=smp

What Are The Main Market Drivers Shaping The Progression Of The Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market?
The rising prevalence of prostate cancer is expected to propel the growth of the castration-resistant prostate cancer (CRPC) or hormone-refractory prostate cancer (HRPCA) therapeutics market going forward. Prostate cancer refers to a type of cancer that develops in the prostate gland, a small gland in men located below the bladder and in front of the rectum. The rising prevalence of prostate cancer is due to the aging population, as the risk of developing prostate cancer increases significantly with age. Castration-resistant prostate cancer (CRPC) or hormone-refractory prostate cancer (HRPCA) therapeutics help in treating prostate cancer by targeting advanced stages of the disease that no longer respond to conventional hormone therapy. They improve patient outcomes by slowing disease progression and managing symptoms, thereby enhancing quality of life. For instance, in October 2025, according to NHS Digital, a UK-based government agency responsible for healthcare data and statistics, there were 58,137 new diagnoses of prostate cancer in England in 2023, representing a 6 percent increase compared with 2022. Therefore, the rising prevalence of prostate cancer is driving the growth of the castration-resistant prostate cancer (CRPC) or hormone-refractory prostate cancer (HRPCA) therapeutics market.

What Leading Segment Types Are Used To Analyze The Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market?
The castration-resistant prostate cancer (crpc) or hormone-refractory prostate cancer (hrpca) therapeutics market covered in this report is segmented –

1) By Therapy Type: Hormonal Therapy, Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy
2) By Route Of Administration: Oral, Injectable, Intravenous
3) By End User: Hospitals, Oncology Centers, Ambulatory Surgical Centers, Other End Users

Subsegments:
1) By Hormonal Therapy: Androgen Receptor (AR) Inhibitors, Androgen Synthesis Inhibitors, Luteinizing Hormone-Releasing Hormone (LHRH) Agonists Or Antagonists, Gonadotropin-Releasing Hormone (GnRH) Agonists Or Antagonists
2) By Chemotherapy: Taxanes, Platinum-Based Agents, Other Chemotherapies
3) By Immunotherapy: Immune Checkpoint Inhibitors, Cancer Vaccines
4) By Targeted Therapy: Poly ADP-Ribose Polymerase (PARP) Inhibitors, Phosphoinositide 3-Kinase (PI3K) Or Protein Kinase B (PI3K) Or Mammalian Target Of Rapamycin (mTOR) Inhibitors, Tyrosine Kinase Inhibitors (TKIs), Deoxyribonucleic Acid Damage Response (DDR) Inhibitors
5) By Radiation Therapy: External Beam Radiation Therapy, Brachytherapy, Radiopharmaceuticals

What Key Market Trends Are Contributing To The Ongoing Development Of The Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market?
Major companies operating in the castration-resistant prostate cancer (CRPC) or hormone-refractory prostate cancer (HRPCA) therapeutics market are focusing on developing innovative products and getting approvals, such as dual-action tablets, to enhance treatment efficacy and patient outcomes. Dual-action tablets refer to advanced formulations that combine two therapeutic agents in a single dose to simultaneously target multiple pathways in castration-resistant prostate cancer (CRPC) treatment. For instance, in August 2023, Janssen Pharmaceuticals, a Belgium-based pharmaceutical company, received approval from the U.S. Food and Drug Administration (FDA) for Akeega, a novel tablet developed for the treatment of adults with BRCA-mutated metastatic castration-resistant prostate cancer (mCRPC). Akeega is a precision medicine that combines a PARP inhibitor (niraparib) with a CYP17 inhibitor (abiraterone acetate), specifically targeting patients with BRCA mutations. When used alongside prednisone, it significantly enhances radiographic progression-free survival (rPFS) compared to conventional hormonal therapy alone.

Who Are The Core Market Contributors Recognized Within The Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market Ecosystem?
Major companies operating in the castration-resistant prostate cancer (crpc) or hormone-refractory prostate cancer (hrpca) therapeutics market are Pfizer Inc., Johnson And Johnson, Merck & Co. Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Takeda Pharmaceutical Company Limited, Astellas Pharma Inc., Daiichi Sankyo Co. Ltd., Lantheus Holdings Inc., POINT Biopharma Global Inc., Clovis Oncology Inc., Arvinas Inc., Clarity Pharmaceuticals Ltd, Modra Pharmaceuticals B.V., Oncternal Therapeutics Inc., Zenith Epigenetics Ltd., ESSA Pharma Inc.

Get Your In-Depth Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market Report Now:
https://www.thebusinessresearchcompany.com/report/castration-resistant-prostate-cancer-crpc-or-hormone-refractory-prostate-cancer-hrpca-therapeutics-global-market-report

Which Locations Are Showing Rapid Adoption And Strong Growth Indicators In The Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market?
North America was the largest region in the castration-resistant prostate cancer (CRPC) or hormone-refractory prostate cancer (HRPCA) therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the castration-resistant prostate cancer (crpc) or hormone-refractory prostate cancer (hrpca) therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Contact Us:

The Business Research Company: https://thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: info@tbrc.info

Follow Us On:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

Comments

Post a Comment

Popular posts from this blog

Glycomics or Glycobiology Market Scope, Share Analysis And Growth 2025

Image
Backed by rigorous analysis and deep industry knowledge, this study is designed to support growth and investment decisions in the glycomics or glycobiology market. How Big Is The Glycomics or Glycobiology Market In 2025? The glycomics or glycobiology market size has grown rapidly in recent years. It will grow from $1.85 billion in 2024 to $2.13 billion in 2025 at a compound annual growth rate (CAGR) of 14.9%. The growth in the historic period can be attributed to increased awareness of glycans in biological systems, expansion of glycan-related database and resources, rise in collaborative research initiatives, advancements in glycan synthesis and engineering, glycan biomarker identification. The glycomics or glycobiology market size is expected to see rapid growth in the next few years. It will grow to $3.99 billion in 2029 at a compound annual growth rate (CAGR) of 17.0%. The growth in the forecast period can be attributed to glycan-focused artificial intelligence (AI) and data analy...
Read more

Hypertrophic Cardiomyopathy (HCM) Therapeutics Market Scope, Share Analysis And Growth 2025

Image
Focused on real-world business use, this report highlights what’s changing in the hypertrophic cardiomyopathy (hcm) therapeutics market and what companies should prepare for next. What Is The Projected Market Size & Growth Rate Of The Hypertrophic Cardiomyopathy (HCM) Therapeutics Market? The hypertrophic cardiomyopathy (hcm) therapeutics market size has grown marginally in recent years. It will grow from $1.34 billion in 2024 to $1.37 billion in 2025 at a compound annual growth rate (CAGR) of 1.5%. The growth in the historic period can be attributed to diagnostic advancements, increased disease awareness, drug development and approvals, rising healthcare expenditure, government initiatives and funding. The hypertrophic cardiomyopathy (hcm) therapeutics market size is expected to see steady growth in the next few years. It will grow to $1.56 billion in 2029 at a compound annual growth rate (CAGR) of 3.4%. The growth in the forecast period can be attributed to genetic research and ...
Read more

Smart Crop Monitoring Market Overview, Analysis And Demand By 2034

Image
Aimed at strategic decision-makers, this report explores current opportunities, emerging trends, and market dynamics shaping the smart crop monitoring sector. How Big Is The Smart Crop Monitoring Market In 2025? The smart crop monitoring market size has grown rapidly in recent years. It will grow from $3.47 billion in 2024 to $4.09 billion in 2025 at a compound annual growth rate (CAGR) of 18.0%. The growth in the historic period can be attributed to rising demand for high crop production, increasing global population, significant growth in IOT technology, rising need for sustainable agricultural practices, and increasing regulatory pressures. The smart crop monitoring market size is expected to see rapid growth in the next few years. It will grow to $7.83 billion in 2029 at a compound annual growth rate (CAGR) of 17.6%. The growth in the forecast period can be attributed to the development of automated irrigation systems, the growing trend of farm-to-table movements, an increase in ag...
Read more